Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Change in Receivables data on record, last reported at -$22.6 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 21240.57% year-over-year to -$22.6 million; the TTM value through Dec 2025 reached -$17.2 million, down 489.76%, while the annual FY2025 figure was -$17.2 million, 489.76% down from the prior year.
  • Change in Receivables reached -$22.6 million in Q4 2025 per COLL's latest filing, down from $20.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $58.9 million in Q3 2021 and bottomed at -$43.2 million in Q4 2021.
  • Average Change in Receivables over 5 years is $1.4 million, with a median of -$1.1 million recorded in 2022.
  • The widest YoY moves for Change in Receivables: up 10913.68% in 2025, down 21240.57% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$43.2 million in 2021, then surged by 71.54% to -$12.3 million in 2022, then skyrocketed by 81.06% to -$2.3 million in 2023, then soared by 95.44% to -$106000.0 in 2024, then crashed by 21240.57% to -$22.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$22.6 million in Q4 2025, $20.9 million in Q3 2025, and -$15.7 million in Q2 2025.